» Articles » PMID: 35277527

AC010973.2 Promotes Cell Proliferation and is One of Six Stemness-related Genes That Predict Overall Survival of Renal Clear Cell Carcinoma

Overview
Journal Sci Rep
Specialty Science
Date 2022 Mar 12
PMID 35277527
Authors
Affiliations
Soon will be listed here.
Abstract

Extensive research indicates that tumor stemness promotes tumor progression. Nonetheless, the underlying roles of stemness-related genes in renal clear cell carcinoma (ccRCC) are unclear. Data used in bioinformatics analysis were downloaded from The Cancer Genome Atlas (TCGA) database. Moreover, the R software, SPSS, and GraphPad Prism 8 were used for mapping and statistical analysis. First, the stemness index of each patient was quantified using a machine learning algorithm. Subsequently, the differentially expressed genes between high and low stemness index were identified as stemness-related genes. Based on these genes, a stable and effective prognostic model was identified to predict the overall survival of patients using a random forest algorithm (Training cohort; 1-year AUC: 0.67; 3-year AUC: 0.79; 5-year AUC: 0.73; Validation cohort; 1-year AUC: 0.66; 3-year AUC: 0.71; 5-year AUC: 0.7). The model genes comprised AC010973.2, RNU6-125P, AP001209.2, Z98885.1, KDM5C-IT1, and AL021368.3. Due to its highest importance evaluated by randomforst analysis, the AC010973.2 gene was selected for further research. In vitro experiments demonstrated that AC010973.2 is highly expressed in ccRCC tissue and cell lines. Meanwhile, its knockdown could significantly inhibit the proliferation of ccRCC cells based on colony formation and CCK8 assays. In summary, our findings reveal that the stemness-related gene AC01097.3 is closely associated with the survival of patients. Besides, it remarkably promotes cell proliferation in ccRCC, hence a novel potential therapeutic target.

Citing Articles

Identification of anoikis-related molecular patterns and the novel risk model to predict prognosis, tumor microenvironment infiltration and immunotherapy response in bladder cancer.

Zhu L, Xiao F, Hou Y, Huang S, Xu Y, Guo X Front Immunol. 2024; 15:1491808.

PMID: 39664392 PMC: 11631915. DOI: 10.3389/fimmu.2024.1491808.


Development and validation of a radiomic prediction model for TACC3 expression and prognosis in non-small cell lung cancer using contrast-enhanced CT imaging.

Bai W, Zhao X, Ning Q Transl Oncol. 2024; 51:102211.

PMID: 39603208 PMC: 11635781. DOI: 10.1016/j.tranon.2024.102211.


Leveraging MRI radiomics signature for predicting the diagnosis of CXCL9 in breast cancer.

Yan L, Chen Y, He J Heliyon. 2024; 10(19):e38640.

PMID: 39430466 PMC: 11490775. DOI: 10.1016/j.heliyon.2024.e38640.


Epigenetic dysregulated long non-coding RNAs in renal cell carcinoma based on multi-omics data and their influence on target drugs sensibility.

Wang J, Dou P, Sun Y, Zheng J, Wu G, Liu H Front Genet. 2024; 15:1406150.

PMID: 39156959 PMC: 11327069. DOI: 10.3389/fgene.2024.1406150.


Fc receptor-like A promotes malignant behavior in renal cell carcinoma and correlates with tumor immune infiltration.

Liu J, Jiang Y, Liu J, Tian C, Lin Y, Yang Y Cancer Med. 2024; 13(15):e70072.

PMID: 39108036 PMC: 11303447. DOI: 10.1002/cam4.70072.


References
1.
Zhang Y, Tang B, Song J, Yu S, Li Y, Su H . Lnc-PDZD7 contributes to stemness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression. J Exp Clin Cancer Res. 2019; 38(1):92. PMC: 6381703. DOI: 10.1186/s13046-019-1106-2. View

2.
Liu C, Chen B, Huang Z, Hu C, Jiang L, Zhao C . Comprehensive analysis of a 14 immune-related gene pair signature to predict the prognosis and immune features of gastric cancer. Int Immunopharmacol. 2020; 89(Pt B):107074. DOI: 10.1016/j.intimp.2020.107074. View

3.
Ma F, Liu X, Zhou S, Li W, Liu C, Chadwick M . Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop. Cancer Lett. 2019; 450:63-75. DOI: 10.1016/j.canlet.2019.02.008. View

4.
Sanchez-Gastaldo A, Kempf E, Del Alba A, Duran I . Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat Rev. 2017; 60:77-89. DOI: 10.1016/j.ctrv.2017.08.010. View

5.
Piao L, Feng Y, Che N, Li M, Li X, Jin Y . SETD8 is a prognostic biomarker that contributes to stem-like cell properties in non-small cell lung cancer. Pathol Res Pract. 2020; 216(12):153258. DOI: 10.1016/j.prp.2020.153258. View